49 completed, 13 unknown, 5 recruiting, 3 terminated. 22 Phase 1, 15 Phase 3, 15 Phase 4, 11 Not applicable, 7 Phase 2.
Follow Fluvoxamine: new trials by email Literature Review of Fluvoxamine trials Research Report on Fluvoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 Fluvoxamine, Placebo - Post-COVID, POST-Covid 19 | Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 160 | 2026-06-04 | 2026-06-09 |
| Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery Fluvoxamine, Placebo - Delirium, Surgery-Complications | Phase 3 | Recruiting | Washington University School of Medicine | 46 | 2026-04-06 | 2026-04-29 |
| Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study) Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine) - Cardiovascular Diseases (CVD), Depression Anxiety Disorder | Not applicable | Recruiting | Guangdong Provincial People's Hospital | 106 | 2025-04-22 | 2025-06-17 |
| To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers KP-001, Rosuvastatin calcium10mg, Caffeine citrate - Healty Volunteers | Phase 1 | Completed | Kaken Pharmaceutical | 38 | 2025-02-13 | 2025-09-12 |
| Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants SSRI - Depression, Inflammation | Completed | Germans Trias i Pujol Hospital | 50 | 2024-04-01 | 2026-09-14 | |
| Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction | Phase 1 | Completed | Asceneuron S.A. | 50 | 2024-02-22 | 2024-12-18 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet - Long COVID-19 Syndrome, Chronic Fatigue Syndrome | Phase 3 | Completed | Cardresearch | 399 | 2023-10-18 | 2026-04-13 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects Savolitinib, Fluvoxamine - Healthy Male Subjects | Phase 1 | Completed | AstraZeneca | 16 | 2023-06-02 | 2023-08-29 |
| Fluvoxamine for Long COVID-19 Fluvoxamine - Long COVID | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 191 | 2023-05-15 | 2026-10-07 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant Miricorilant, Fluvoxamine - Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 26 | 2023-01-24 | 2023-03-22 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1208 | 2022-08-25 | 2024-11-15 |
| Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status Voriconazole 200mg, FluvoxaMINE 50 Mg Oral Tablet, Omeprazole 10 MG Oral Tablet - Healthy | Phase 1 | Unknown | University Hospital, Geneva | 45 | 2022-04-01 | 2022-11-03 |
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia Fluvoxamine, Placebo - COVID-19, Olfactory Disorder | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-12-14 | 2022-03-11 | |
| Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community FluvoxaMINE Maleate 50 MG, Fluvoxamine, Bromhexine, Fluvoxamine, Cyproheptadine - Treatment Efficacy | Phase 4 | Completed | Chulalongkorn University | 1200 | 2021-10-01 | 2022-11-04 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1331 | 2021-06-08 | 2023-09-26 |
| ACTIV-6: COVID-19 Study of Repurposed Medications Ivermectin, Fluvoxamine, Fluticasone - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 10956 | 2021-06-08 | 2025-11-17 |
| Electronic Training of Elderly Depression With Cognitive Impairment Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram） - Geriatric Depression, Cognitive Impairment | Not applicable | Completed | Capital Medical University | 128 | 2021-05-18 | 2024-07-16 |
| Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG - Covid19, SARS-Associated Coronavirus | Phase 3 | Unknown | Cardresearch | 7819 | 2021-01-19 | 2024-05-08 |
Showing 20 of 73. Sign in to see all of them.
Depression (11) · COVID-19 (10) · Obsessive-Compulsive Disorder (10) · Depressive Disorder, Major (5) · Coronavirus Infections (4) · Depressive Disorder (4) · Schizophrenia (4) · Anxiety Disorders (3) · Post-Acute COVID-19 Syndrome (3) · Anxiety, Separation (2) · Cognitive Dysfunction (2) · Generalized Anxiety Disorder (2) · Phobia, Social (2) · Severe Acute Respiratory Syndrome (2) · Acute Kidney Injury (1)
Shanghai Mental Health Center (6) · Washington University School of Medicine (5) · Susanna Naggie, MD (3) · AstraZeneca (2) · Cardresearch (2) · Celgene (2) · Duke University (2) · Hadassah Medical Organization (2) · National Institute of Mental Health (NIMH) (2) · Sha'ar Menashe Mental Health Center (2) · Solvay Pharmaceuticals (2) · AbbVie (1) · Abivax S.A. (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asan Medical Center (1)
United States (25) · China (12) · Canada (5) · Brazil (3) · Germany (3) · Israel (3) · Japan (3) · Netherlands (3) · Switzerland (3) · United Kingdom (3) · France (2) · Denmark (1) · Hungary (1) · Italy (1) · Russia (1)
Adrian Hernandez, MD (3) · Susanna Naggie, MD (3) · Gilmar Reis, MD,PhD. (2) · Toshiaki Yamaguchi (2) · Yifeng Shen, Senior (2) · Alexey E. Bobrov, Professor (1) · Ben Palanca, MD (1) · Cameron Hurst, PhD (1) · Caroline Samer, Prof (1) · Carolyn Bramante, MD (1) · Chantal Csajka, Prof PhD (1) · Christophe G Lambert, PhD (1)
PMID 35180412, PMID 19183470, PMID 19574030, PMID 21934055, PMID 22940498, PMID 25457929, PMID 25689244, PMID 26231193, PMID 26799332, PMID 27130272, PMID 28412602, PMID 28688742, PMID 28901625, PMID 29101463, PMID 29920885, PMID 30986735, PMID 31237566, PMID 31651956, PMID 31744781, PMID 31807102, PMID 32162723, PMID 32307692, PMID 32746941, PMID 33116533, PMID 33180097, PMID 33240091, PMID 33688834, PMID 33688908, PMID 34225296, PMID 34717820, PMID 34927127, PMID 34932440, PMID 35018097, PMID 35076931, PMID 35353979, PMID 35384422, PMID 35651818, PMID 35979039, PMID 35982649, PMID 35982669, PMID 36070710, PMID 36124697, PMID 36189181, PMID 36269852, PMID 36516104, PMID 36561174, PMID 36633838, PMID 36780676, PMID 36807465, PMID 37068273
U24TR001608 (3), 2016 (2), 2018 (1), R01MH055121 (1), R21AG086855 (1), UH3MH106338 (1)